

Diese Meldung wurde von presstext ausgedruckt und ist unter <https://www.presstext.com/news/20251125031> abrufbar.

pta20251125031

Public disclosure of inside information according to article 17 MAR

Leo International Precision Health Aktiengesellschaft: Announcement regarding the issuance of new shares from authorized capital excluding subscription rights

Planegg / Martinsried (pta031/25.11.2025/20:45 UTC+1)

On November 25, 2025, the Executive Management Board of Leo International Precision Health Aktiengesellschaft (the "Company"), with the approval of the Supervisory Board on the same day, has resolved, with partial use of the authorization pursuant to Section 4 (3) of the Company's Articles of Association (Authorized Capital 2025), to increase the Company's share capital by EUR 50,000.00 to EUR 550,000.00 through a capital increase in kind of EUR 500,000.00 by issuing 50,000 new no-par value bearer shares with full profit participation rights as of January 1, 2025, in exchange for contributions in kind. The contributions in kind consist of shares in Danner Laboratory, Inc., Immune Anima Inc., PATHOMICS HEALTH PTE. LTD., Rehne Biotech (Australia) Pty Ltd, amiko AI Biomedical Limited, and Wankang Medical Group (Hong Kong) Co., Limited.

Shareholders' subscription rights were excluded in accordance with Section 4 (3) sentence 3, third bullet point, of the Company's Articles of Association.

The capital increase through contributions in kind will take effect upon the pending entry in the commercial register of the Düsseldorf Local Court.

Düsseldorf, November 2025

Leo International Precision Health Aktiengesellschaft

Executive Management Board

(end)

Emitter:	Leo International Precision Health Aktiengesellschaft Am Kopferspitz 19 82152 Planegg / Martinsried Germany
Contact Person:	Phillip Campbell
E-Mail:	vorstand@spobag-ag.de
ISIN(s):	DE0005490601 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt